3rd Rare & Genetic Kidney Disease Drug Development Summit

The 3rd Rare & Genetic Kidney Disease Drug Development Summit is a premier industry event dedicated to accelerating the development of therapeutic treatments for rare and genetic kidney diseases such as IgA nephropathy (IgAN), focal segmental glomerulosclerosis (FSGS), Alport syndrome, polycystic kidney disease (PKD), and more.

This summit brings together a diverse community of over 100 experts, including representatives from regulatory agencies like the FDA and EMA, leading biotech and pharmaceutical companies such as Chinook Therapeutics, Novo Nordisk, Janssen, Travere Therapeutics, Otsuka, and other key stakeholders in the field.

The event aims to foster collaboration and knowledge sharing among participants to advance the frontiers of novel therapies for these conditions. With the acceptance of estimated glomerular filtration rate (eGFR) as a surrogate endpoint and the recent breakthroughs in genetic therapies and disease pathology sequencing, there is an exciting opportunity to expedite the approval and development of precision medicine for patients with rare and genetic kidney diseases.

Participants will have the opportunity to gain instrumental insights into patients' unique experiences, explore kidney-specific modes of action, and delve into adaptive trial designs. The summit will focus on the potential of RNA-based therapeutics, unraveling biomarkers and their role in precision medicine, and addressing the barriers to achieving diversity in clinical trials.

By bringing together key stakeholders and experts, this event seeks to drive innovation, collaboration, and the exchange of cutting-edge knowledge to advance the development of effective treatments for rare and genetic kidney diseases. Ultimately, the goal is to improve patient outcomes, enhance the understanding of these conditions, and pave the way for more targeted and personalized therapies.